Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (81-90 of 247) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulationsE Claire Dees, Roger B Cohen, Margaret von Mehren, et al.
The Oncologist|March 11, 2022
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World SettingsEmma G Sturgill, Amanda Misch, Carissa C Jones, et al.
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancerPatricia M LoRusso, Suzanne F Jones, Kevin M Koch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2007
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkDavid R Spigel, John D Hainsworth, Lisa Simons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junctionDavid R Spigel, F Anthony Greco, Anthony A Meluch, et al.
Breast Cancer Research and Treatment|October 29, 2015
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence scoreDenise A Yardley, Nancy W Peacock, Mythili Shastry, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2010
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancerJeffrey R Infante, Suzanne F Jones, Johanna C Bendell, et al.
ESMO Open|August 30, 2017
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortHoward A Burris, Suzanne Bakewell, Johanna C Bendell, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research ConsortiumDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Pageof 25

Showing results (81-90 of 247) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulationsE Claire Dees, Roger B Cohen, Margaret von Mehren, et al.
The Oncologist|March 11, 2022
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World SettingsEmma G Sturgill, Amanda Misch, Carissa C Jones, et al.
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancerPatricia M LoRusso, Suzanne F Jones, Kevin M Koch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2007
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkDavid R Spigel, John D Hainsworth, Lisa Simons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junctionDavid R Spigel, F Anthony Greco, Anthony A Meluch, et al.
Breast Cancer Research and Treatment|October 29, 2015
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence scoreDenise A Yardley, Nancy W Peacock, Mythili Shastry, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2010
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancerJeffrey R Infante, Suzanne F Jones, Johanna C Bendell, et al.
ESMO Open|August 30, 2017
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortHoward A Burris, Suzanne Bakewell, Johanna C Bendell, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research ConsortiumDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Pageof 25